Evaluate Oral Topotecan With HM30181A Monotherapy in Patients With Advanced Malignancies
Status:
Completed
Trial end date:
2021-01-09
Target enrollment:
Participant gender:
Summary
This is a multicenter, nonrandomized, open-label, safety, tolerability and pharmacokinetic
(PK) study to determine the MTD and optimal dosing of Oratopo. No control group has been
included.